- Home
- HCI vs VIR Comparison
HCI vs VIR Comparison
Compare HCI & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCI
- VIR
- Stock Information
- Founded
- HCI 2006
- VIR 2016
- Country
- HCI United States
- VIR United States
- Employees
- HCI N/A
- VIR N/A
- Industry
- HCI Property-Casualty Insurers
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- HCI Finance
- VIR Health Care
- Exchange
- HCI Nasdaq
- VIR Nasdaq
- Market Cap
- HCI 1.2B
- VIR 1.0B
- IPO Year
- HCI N/A
- VIR 2019
- Fundamental
- Price
- HCI $114.47
- VIR $7.27
- Analyst Decision
- HCI Buy
- VIR Buy
- Analyst Count
- HCI 5
- VIR 5
- Target Price
- HCI $140.00
- VIR $36.40
- AVG Volume (30 Days)
- HCI 112.1K
- VIR 1.2M
- Earning Date
- HCI 11-07-2024
- VIR 02-20-2025
- Dividend Yield
- HCI 1.40%
- VIR N/A
- EPS Growth
- HCI 163.93
- VIR N/A
- EPS
- HCI 11.94
- VIR N/A
- Revenue
- HCI $750,846,000.00
- VIR $78,618,000.00
- Revenue This Year
- HCI N/A
- VIR N/A
- Revenue Next Year
- HCI $14.52
- VIR N/A
- P/E Ratio
- HCI $9.58
- VIR N/A
- Revenue Growth
- HCI 48.73
- VIR N/A
- 52 Week Low
- HCI $81.35
- VIR $6.56
- 52 Week High
- HCI $126.50
- VIR $13.09
- Technical
- Relative Strength Index (RSI)
- HCI 49.20
- VIR 42.92
- Support Level
- HCI $112.81
- VIR $7.22
- Resistance Level
- HCI $119.73
- VIR $7.64
- Average True Range (ATR)
- HCI 4.23
- VIR 0.35
- MACD
- HCI 0.12
- VIR -0.01
- Stochastic Oscillator
- HCI 56.83
- VIR 30.43
About HCI HCI Group Inc.
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are HCPCI insurance operations, TypTap Group, Real estate operations, and Corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.